Dr Hugh Marston, head of Global CNS Diseases at Boehringer Ingelheim (BI), is the industry lead on the PRISM project. He discusses the industry perspective with ECNP Press Officer, Tom Parkhill.
Click here to read the full interview.
Dr Hugh Marston, head of Global CNS Diseases at Boehringer Ingelheim (BI), is the industry lead on the PRISM project. He discusses the industry perspective with ECNP Press Officer, Tom Parkhill.
Click here to read the full interview.
The PRISM 2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034377. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, and Cohen Veterans Bioscience (CVB). The website reflects only the authors' views and IMI JU, EFPIA, CVB, and the European Commission are not responsible for any use that may be made of the information it contains.